HCA 8-K Current Reports
HCA Healthcare, Inc. - 413 current reports
HCA Healthcare, Inc. 8-K Report, Executive Changes (Jun 18, 2026)
HCA Healthcare, Inc. has announced a significant leadership change with the upcoming departure of Dr. Michael Cuffe from his role as Executive Vice President and Chief Clinical Officer. This transition is effective August 31, 2026, after which Dr. Cuffe will remain with the company in a transitional capacity until February 2027. This move signifies a shift in the company's executive team, and investors will want to monitor the strategic implications and the appointment of a successor to this critical clinical leadership position.
HCA Healthcare, Inc. 8-K Report, Material Agreement (Apr 30, 2026)
HCA Healthcare, Inc. (HCA) announced through its subsidiary, HCA Inc., the successful completion of a public offering of $3 billion in aggregate principal amount of senior unsecured notes. The offering is comprised of three tranches: $1 billion of 4.700% Senior Notes due 2031, $750 million of 5.000% Senior Notes due 2033, and $1.25 billion of 5.300% Senior Notes due 2036. These notes are guaranteed on a senior unsecured basis by the Parent Guarantor, HCA Healthcare, Inc. This significant debt issuance, registered under a shelf registration statement, will increase HCA's leverage but provides substantial capital. Investors should note the varying interest rates and maturity dates, which reflect market conditions and the company's long-term financing strategy. The company has entered into an underwriting agreement with several major investment banks for this offering, and detailed terms, including covenants, optional redemption, and change of control provisions, are outlined in the respective indentures filed with the SEC.
HCA Healthcare, Inc. 8-K Report, Shareholder Vote Results (Apr 28, 2026)
HCA Healthcare, Inc. (HCA) filed an 8-K on April 28, 2026, detailing the results of its Annual Meeting of Stockholders held on April 23, 2026. The meeting saw strong participation, with over 209 million shares represented. A key outcome was the overwhelming election of all nine director nominees to the Board of Directors, indicating robust shareholder confidence in the current leadership and governance structure. Furthermore, the Company's appointment of Ernst & Young LLP as its independent registered public accounting firm for 2026 received broad ratification, underscoring shareholder trust in the auditing process. Shareholder approval was also given to the advisory resolution on executive compensation, suggesting alignment between management's pay practices and investor sentiment. However, two shareholder proposals, one concerning healthcare consequences reporting and another on shareholders' right to act by written consent, failed to gain majority support.
HCA Healthcare, Inc. 8-K Report, Corporate Update (Apr 27, 2026)
HCA Healthcare, Inc. (HCA) announced through a press release filed on April 27, 2026, that its wholly-owned subsidiary, HCA Inc., is initiating a public offering of senior unsecured notes. This offering is intended to fund the redemption of two existing note issuances: $1.500 billion of 5.250% senior notes due June 2026 and $1.000 billion of 5.375% senior notes due September 2026. The redemption of these notes, totaling $2.5 billion, is scheduled for May 27, 2026, and is contingent on the successful completion of the new note offering. This strategic move suggests HCA is proactively managing its debt maturity profile and potentially aiming to refinance at more favorable terms or reduce overall interest expense. Investors should monitor the terms of the new offering and HCA's overall debt strategy.
HCA Healthcare, Inc. 8-K Report, Financial Results (Apr 24, 2026)
HCA Healthcare, Inc. has filed an 8-K report on April 24, 2026, to disclose its financial results for the first quarter ended March 31, 2026. The press release, included as an exhibit, provides details on the company's operational performance during the period. While the filing itself does not contain detailed financial figures, it points investors to the press release for the specific results and operational metrics. Investors should review Exhibit 99.1 for comprehensive information regarding HCA's Q1 2026 performance. Additionally, the company announced a quarterly cash dividend of $0.78 per share, payable on June 30, 2026, to shareholders of record as of June 16, 2026. This dividend declaration signifies the company's continued commitment to returning capital to its shareholders and provides a component of return for investors.
HCA Healthcare, Inc. 8-K Report, Executive Changes (Feb 25, 2026)
HCA Healthcare, Inc. (HCA) announced the adoption of its 2026 Executive Officer Performance Excellence Program (Executive Officer PEP) on February 24, 2026. This program outlines how the company's executive officers will be eligible to earn performance-based cash awards. The compensation structure is heavily weighted towards financial performance, with 80% of awards tied to EBITDA targets and 20% linked to quality metrics. This emphasis signals a continued focus on profitability while also incorporating critical patient care and experience indicators. Investors should note the specific award opportunities, which range from 175% of base salary for the CEO down to 100% for other named executive officers. The program details tiered payouts for EBITDA performance, with potential for awards to double the target amount at maximum performance. The quality metrics component is also subject to tiered payouts and can be forfeited entirely if EBITDA falls below 90% of target, reinforcing the primacy of financial results. The Compensation Committee retains discretion over adjustments and clawbacks, providing flexibility and risk mitigation.
HCA Healthcare, Inc. 8-K Report, Financial Results (Jan 27, 2026)
HCA Healthcare, Inc. (HCA) filed an 8-K on January 27, 2026, reporting its financial and operational results for the fourth quarter and full year ended December 31, 2025. While the 8-K itself primarily references a press release (Exhibit 99.1) for detailed financial performance, it directly discloses two significant capital allocation decisions by the Board of Directors. These decisions are a substantial $10 billion share repurchase authorization and the declaration of a quarterly cash dividend of $0.78 per share. These announcements indicate a strong focus on returning capital to shareholders. The large share repurchase program suggests management's confidence in the company's valuation and future prospects, potentially signaling a belief that the stock is undervalued. The consistent dividend payment further reinforces a commitment to shareholder returns. Investors will want to closely examine the detailed financial results in the referenced press release to understand the underlying performance driving these capital allocation decisions.
HCA Healthcare, Inc. 8-K Report, Material Agreement (Oct 31, 2025)
HCA Healthcare, Inc. (HCA) announced the successful completion of a significant public offering of senior notes, raising a total of $3.25 billion. The offering was structured across four tranches with varying maturities and coupon rates: $500 million of 4.300% Senior Notes due 2030, $1 billion of 4.600% Senior Notes due 2032, $1 billion of 4.900% Senior Notes due 2035, and $750 million of 5.700% Senior Notes due 2055. These notes are guaranteed by the parent company, HCA Healthcare, Inc., and represent senior unsecured obligations of the subsidiary issuer. The proceeds from this offering will likely be used to fund general corporate purposes or existing debt refinancing, though specific use of proceeds is not detailed in this filing. The company has also entered into an underwriting agreement with several prominent financial institutions to facilitate this issuance. This move indicates HCA's ongoing strategy to manage its capital structure and potentially fund future growth or operational needs.
HCA Healthcare, Inc. 8-K Report, Corporate Update (Oct 27, 2025)
HCA Healthcare, Inc. (HCA) announced through a press release dated October 27, 2025, the commencement of a proposed public offering of senior unsecured notes by its wholly owned subsidiary, HCA Inc. This offering aims to raise capital, and the specific use of proceeds will be detailed further. Concurrently, HCA Inc. has elected to redeem all of its $1.500 billion of 5.875% senior notes due 2026. This redemption is contingent upon the successful receipt of proceeds from the new note offering and is scheduled for November 26, 2025. This strategic move suggests HCA is likely refinancing existing debt, potentially to lower its interest expenses or extend its maturity profile.
HCA Healthcare, Inc. 8-K Report, Financial Results (Oct 24, 2025)
HCA Healthcare, Inc. (HCA) has filed an 8-K report on October 24, 2025, primarily to announce its third-quarter results for the period ending September 30, 2025, via a press release (Exhibit 99.1). While the full financial details are within the press release, this filing serves as official notification of the company's operational and financial performance for the quarter. Investors should refer to the press release for comprehensive information regarding revenue, profitability, and any forward-looking guidance. In addition to the quarterly results, HCA Healthcare announced a quarterly cash dividend of $0.72 per share. This dividend payment, scheduled for December 29, 2025, to stockholders of record on December 15, 2025, demonstrates the company's commitment to returning capital to its shareholders. This dividend declaration is a significant event for income-focused investors.
HCA Healthcare, Inc. 8-K Report, Financial Results (Jul 25, 2025)
HCA Healthcare, Inc. (HCA) has filed an 8-K report detailing its second quarter 2025 results and announcing a quarterly cash dividend. The press release, attached as Exhibit 99.1, is the primary source of operational and financial information for the quarter ended June 30, 2025. Investors should review this press release for specific financial performance metrics and commentary on the company's condition. In addition to its quarterly results, HCA's Board of Directors has declared a quarterly cash dividend of $0.72 per share. This demonstrates a commitment to returning capital to shareholders and provides income-generating potential for investors holding the stock. The dividend payment is scheduled for September 30, 2025, to shareholders of record on September 16, 2025.
HCA Healthcare, Inc. 8-K Report, Executive Changes (Jul 11, 2025)
HCA Healthcare, Inc. (HCA) announced a key board change with the appointment of John W. Chidsey, III to its Board of Directors, effective July 15, 2025. This appointment will increase the size of the board from nine to ten members. Mr. Chidsey's addition is intended to bring new perspectives and expertise to the company's governance. Mr. Chidsey has been appointed to serve on three critical board committees: the Audit and Compliance Committee, the Compensation Committee, and the Patient Safety and Quality of Care Committee. His involvement in these committees suggests a focus on financial oversight, executive remuneration, and the company's core operational quality. Investors should note that his appointment is part of the company's established governance framework, with compensation in line with that of other non-management directors.
HCA Healthcare, Inc. 8-K Report, Financial Obligation (Jun 10, 2025)
HCA Healthcare, Inc. (HCA) has announced the establishment of a commercial paper program through its direct, wholly-owned subsidiary, HCA Inc. This program allows for the issuance of unsecured commercial paper notes up to a maximum aggregate principal amount of $4.0 billion outstanding at any time. The Parent Guarantor, HCA Healthcare, Inc., is providing an unconditional guarantee for these notes, indicating strong financial backing for this new financing facility. The primary purpose of this commercial paper program is to provide HCA with flexible access to short-term funding for general corporate purposes. The notes will have maturities of up to 397 days and will be sold on customary terms in the U.S. commercial paper market. Investors should note that this is a private placement and the securities are not registered under the Securities Act of 1933, meaning they are subject to specific exemptions from registration requirements. This move suggests a proactive approach by HCA to manage its liquidity and working capital needs.
HCA Healthcare, Inc. 8-K Report, Executive Changes (Apr 29, 2025)
HCA Healthcare, Inc. filed an 8-K on April 28, 2025, detailing key corporate governance updates approved at their Annual Meeting on April 24, 2025. The most significant information for investors pertains to changes in Board of Directors compensation and an expansion of the company's stock incentive plan. The Board approved a new compensation program for non-management directors, which includes revised annual retainers for various committee roles and the Chairmanship, along with a significant annual equity award valued at $220,000 in restricted stock units. This reflects an alignment with attracting and retaining experienced leadership. Furthermore, HCA stockholders overwhelmingly approved an amendment to the 2020 Stock Incentive Plan, increasing the share pool by 13,150,000 shares and extending its term to 2035. This provides the company with substantial equity to incentivize future performance and employee retention. Additionally, an amendment to the Certificate of Incorporation to exculpate officers was approved, offering further protection to management. The filing also confirms the election of all nine director nominees and the ratification of Ernst & Young LLP as the independent auditor.
HCA Healthcare, Inc. 8-K Report, Financial Results (Apr 25, 2025)
HCA Healthcare, Inc. (HCA) filed an 8-K on April 25, 2025, primarily to report its first-quarter 2025 financial results, as detailed in an accompanying press release. While the 8-K itself does not provide the specific financial figures, it directs investors to this press release for details on operations and financial condition for the quarter ended March 31, 2025. This filing is crucial for investors seeking to understand the company's recent performance and operational trends. In addition to the financial results announcement, HCA's Board of Directors declared a quarterly cash dividend of $0.72 per share. This dividend, payable on June 30, 2025, to shareholders of record on June 16, 2025, demonstrates a continued commitment to returning capital to shareholders. Investors should review the press release (Exhibit 99.1) for comprehensive details on the company's financial performance and operational highlights for the first quarter.
HCA Healthcare, Inc. 8-K Report, Executive Changes (Feb 24, 2025)
HCA Healthcare, Inc. (HCA) has filed an 8-K report detailing its 2025 Executive Officer Performance Excellence Program (Executive Officer PEP). This new program outlines the performance-based compensation structure for the company's executive officers, aiming to align their incentives with key financial and operational goals. The program emphasizes achievement of EBITDA targets, which represent 80% of the award opportunity, and quality metrics, accounting for the remaining 20%. This structure suggests a strong focus on profitability and operational efficiency, while also incorporating critical quality of care indicators as defined by the company. For investors, the most significant aspect is the direct link between executive compensation and the achievement of specific financial and quality benchmarks. The program details the potential payout percentages based on performance levels, ranging from threshold to maximum achievement, with specific award opportunities tied to base salary for the CEO, CFO, and COO. The inclusion of stringent conditions, such as a minimum EBITDA performance being required for any quality-based payout, underscores the company's commitment to balancing financial success with patient care excellence. The filing also notes the retirement of a Board member, Meg G. Crofton, effective at the upcoming annual meeting.
HCA Healthcare, Inc. 8-K Report, Material Agreement (Feb 21, 2025)
HCA Healthcare, Inc. (HCA) has announced the completion of a significant debt offering, raising $5.25 billion in aggregate principal amount of senior notes through its wholly owned subsidiary, HCA Inc. This offering comprises six tranches with varying maturities and interest rates, including senior notes due 2028, 2030, 2032, 2035, and 2055, as well as floating rate senior notes due 2028. These notes are guaranteed on a senior unsecured basis by HCA Healthcare, Inc. and are intended to provide additional financial flexibility for the company. The issuance was completed on February 21, 2025, under the company's existing shelf registration statement and pursuant to multiple supplemental indentures. The specific terms, including interest rates and payment dates, are detailed for each tranche. The notes rank senior to subordinated debt and equally to other senior indebtedness of the Issuer, but are effectively subordinated to secured debt and structurally subordinated to the debt of HCA's subsidiaries. Covenants within the indentures place limitations on liens, sale-leaseback transactions, and asset disposals. Additionally, provisions for optional redemption, change of control triggers with a repurchase price of 101%, and events of default are outlined.
HCA Healthcare, Inc. 8-K Report, Material Agreement (Feb 20, 2025)
HCA Healthcare, Inc. (HCA) announced through its subsidiary, HCA Inc., the entry into a new, larger senior unsecured revolving credit facility totaling $8.0 billion. This new facility has a five-year term and replaces the company's previous senior secured credit facilities, which included a $3.5 billion revolving credit facility and a $1.238 billion term loan. The company repaid all outstanding obligations under the terminated senior secured facilities immediately prior to entering the new agreement. The refinancing is intended to provide HCA with enhanced financial flexibility for general corporate purposes.
HCA Healthcare, Inc. 8-K Report, Corporate Update (Feb 18, 2025)
HCA Healthcare, Inc. (HCA) announced on February 18, 2025, the commencement of a proposed public offering of senior unsecured notes by its subsidiary, HCA Inc. This offering is part of a larger "Proposed Refinancing Transaction" aimed at overhauling the company's debt structure. Specifically, HCA intends to use the proceeds from the new notes offering, along with potential borrowings from a new senior unsecured credit facility, to repay and terminate its existing senior secured credit facilities, which include a cash flow credit facility and an ABL credit facility. As of February 14, 2025, HCA Inc. had $2.950 billion outstanding under its ABL credit facility, a portion of which was used to retire $2.600 billion of 5.375% Senior Notes due 2025. The company is also establishing an $8.000 billion senior unsecured credit facility with a five-year term to support general corporate purposes, which may include repaying borrowings from this new facility or the ABL credit facility if the overall refinancing is not fully consummated. This move signifies a strategic shift towards unsecured debt and potentially aims to optimize borrowing costs and financial flexibility.
HCA Healthcare, Inc. 8-K Report, Financial Results (Jan 24, 2025)
HCA Healthcare, Inc. (HCA) has filed an 8-K report on January 24, 2025, detailing significant corporate actions and financial updates. The report primarily announces the company's fourth quarter and full-year 2024 results of operations, which are further elaborated in an accompanying press release (Exhibit 99.1). While specific financial figures from the press release are not detailed in the 8-K text itself, this filing serves as the official notification of these results to the market. Beyond the financial results, HCA has made two key capital allocation announcements. The Board of Directors has authorized a substantial new share repurchase program of up to $10 billion, signaling management's confidence in the company's valuation and commitment to returning capital to shareholders. Additionally, the company declared a quarterly cash dividend of $0.72 per share, reinforcing its consistent return of capital strategy.
HCA Healthcare, Inc. 8-K Report, Financial Results (Oct 25, 2024)
HCA Healthcare, Inc. (HCA) filed an 8-K on October 25, 2024, primarily to furnish its third-quarter 2024 earnings press release. While the 8-K itself does not contain detailed financial figures from the press release, it signals the company's official communication of its operational and financial results for the period ending September 30, 2024. Investors should refer to the accompanying press release (Exhibit 99.1) for specific revenue, profit, and operational metrics. In addition to the financial results announcement, HCA's Board of Directors declared a quarterly cash dividend of $0.66 per share. This dividend is payable on December 27, 2024, to shareholders of record as of December 13, 2024. This action indicates continued capital return to shareholders and should be considered by income-focused investors.
HCA Healthcare, Inc. 8-K Report, Material Agreement (Aug 12, 2024)
HCA Healthcare, Inc. (HCA) has filed an 8-K report on August 12, 2024, detailing the completion of a significant public offering of senior notes totaling $3,000,000,000 in aggregate principal amount. This offering consists of three tranches: $750,000,000 of 5.450% Senior Notes due 2031 (New 2031 Notes), $1,250,000,000 of 5.450% Senior Notes due 2034 (2034 Notes), and $1,000,000,000 of 5.950% Senior Notes due 2054 (2054 Notes). These notes are senior unsecured obligations of HCA Inc., guaranteed on a senior unsecured basis by the Parent Guarantor, HCA Healthcare, Inc. The issuance of these notes is a material event for investors as it impacts the company's capital structure and long-term financing. The proceeds from this offering will be used to refinance existing debt and for general corporate purposes, though specific use of proceeds beyond that is not detailed in this filing. The tiered interest rates and maturity dates reflect market conditions and the company's debt management strategy. Investors should note the covenants and change of control provisions detailed in the Indentures, which offer certain protections.
HCA Healthcare, Inc. 8-K Report, Corporate Update (Aug 8, 2024)
HCA Healthcare, Inc. (HCA) announced on August 7, 2024, through an 8-K filing, that it has entered into an Underwriting Agreement to issue and sell $3.0 billion in aggregate principal amount of senior notes. This debt offering consists of three tranches: $750 million of 5.450% Senior Notes due 2031, $1.25 billion of 5.450% Senior Notes due 2034, and $1.0 billion of 5.950% Senior Notes due 2054. These notes will be guaranteed on a senior unsecured basis by the Parent Guarantor, HCA Healthcare, Inc., and are being issued under the company's existing Form S-3 registration statement.
HCA Healthcare, Inc. 8-K Report, Financial Results (Jul 23, 2024)
HCA Healthcare, Inc. (HCA) filed an 8-K on July 23, 2024, primarily to disclose its second-quarter 2024 financial results via a press release. While the specific financial figures are detailed within the attached press release (Exhibit 99.1), the filing itself confirms the company is communicating its operational performance for the period ended June 30, 2024. In addition to the quarterly results, HCA Healthcare also announced a quarterly cash dividend of $0.66 per share. This dividend underscores the company's commitment to returning capital to shareholders and provides a concrete return for investors. The payment date is set for September 30, 2024, with a record date of September 16, 2024, offering investors a clear timeline for dividend receipt.
HCA Healthcare, Inc. 8-K Report, Executive Changes (Apr 30, 2024)
HCA Healthcare, Inc. (HCA) filed an 8-K report on April 29, 2024, detailing key events from its Annual Meeting of Stockholders held on April 25, 2024, and a CFO transition. The report announced the retirement of Executive Vice President and CFO William B. Rutherford, effective May 1, 2024, with Christopher F. Wyatt appointed as the new principal accounting officer while continuing his role as Senior Vice President and Controller. This transition appears smooth with no immediate concerns indicated regarding Mr. Wyatt's appointment. The Annual Meeting saw strong stockholder support for the re-election of all ten director nominees and the ratification of Ernst & Young LLP as the independent registered public accounting firm. Furthermore, stockholders approved a non-binding advisory resolution to hold annual say-on-pay votes, aligning with the board's determination to conduct these votes yearly. Conversely, several stockholder proposals concerning risk mitigation for state restrictions on emergency abortions, patient feedback on care quality, and maternal health outcomes were not approved.
HCA Healthcare, Inc. 8-K Report, Financial Results (Apr 26, 2024)
HCA Healthcare, Inc. (HCA) filed an 8-K on April 26, 2024, primarily announcing its first quarter 2024 financial results via a press release. While specific financial figures are detailed in the referenced Exhibit 99.1, the filing itself serves as notification of these results. Investors should refer to the attached press release for comprehensive details on revenue, profitability, and operational performance during the quarter ended March 31, 2024. Additionally, the Company announced a quarterly cash dividend of $0.66 per share, payable on June 28, 2024, to shareholders of record on June 14, 2024. This dividend declaration underscores HCA's commitment to returning capital to its shareholders and provides a direct financial benefit to investors holding the stock.
HCA Healthcare, Inc. 8-K/A Report, Executive Changes (Feb 26, 2024)
This 8-K/A filing from HCA Healthcare, Inc. serves as an amendment to a previous 8-K announcing the appointment of Michael A. Marks as Executive Vice President and Chief Financial Officer, effective May 1, 2024. The primary purpose of this amendment is to disclose material changes to Mr. Marks' compensation arrangements related to his new role, which were not finalized at the time of the initial filing. Key details of the compensation changes include the establishment of the 2024 Executive Officer Performance Excellence Program (Executive Officer PEP). Under this program, Mr. Marks' performance awards will be weighted 80% towards EBITDA targets and 20% towards specific quality metrics. These quality metrics encompass Healthcare-Associated Infections and Sepsis, Complication and Mortality, and Care Experience. His award opportunity will increase from 65% of base salary to 110% of base salary upon assuming the CFO role.
HCA Healthcare, Inc. 8-K Report, Executive Changes (Feb 26, 2024)
HCA Healthcare, Inc. (HCA) filed an 8-K on February 26, 2024, detailing its 2024 Executive Officer Performance Excellence Program (Executive Officer PEP). This program establishes performance-based compensation for the company's executive officers, with awards weighted 80% on EBITDA targets and 20% on quality metrics. Specific EBITDA targets will be set for the company overall and for key operating groups, while quality metrics will focus on Healthcare-Associated Infections and Sepsis, Complication and Mortality, and Care Experience. Furthermore, the filing announces an adjustment to the compensation for Michael R. McAlevey, who will transition to Executive Vice President – Chief Legal and Administrative Officer on April 1, 2024. This transition includes a base salary increase and a significant long-term equity incentive award. Notably, William B. Rutherford, Executive Vice President and Chief Financial Officer, will retire on May 1, 2024, and will not participate in the Executive Officer PEP.
HCA Healthcare, Inc. 8-K Report, Material Agreement (Feb 23, 2024)
HCA Healthcare, Inc. (HCA) has filed an 8-K report detailing a significant financing transaction. On February 23, 2024, the company, through its subsidiary HCA Inc., successfully completed the public offering of $4.5 billion in aggregate principal amount of senior unsecured notes. These notes are structured across various maturity dates and interest rates, including $1.0 billion of 5.450% notes due 2031, $1.3 billion of 5.600% notes due 2034, $1.5 billion of 6.000% notes due 2054, and $0.7 billion of 6.100% notes due 2064. The parent company, HCA Healthcare, Inc., fully and unconditionally guarantees these notes. This substantial debt issuance, registered under a Form S-3 shelf registration statement, provides HCA with significant capital. The proceeds are intended to fund general corporate purposes, which may include capital expenditures, debt repayment, or acquisitions, although specific use of proceeds is not detailed in this filing. The indenture governing these notes includes standard covenants related to liens, sale and lease-back transactions, and asset disposals, as well as provisions for optional redemption and a change of control repurchase right for noteholders under specific conditions. Investors should note that while these notes are senior unsecured obligations of the issuer, they are effectively subordinated to secured debt and structurally subordinated to the debt and liabilities of HCA's subsidiaries.
HCA Healthcare, Inc. 8-K Report, Corporate Update (Feb 21, 2024)
HCA Healthcare, Inc. (HCA) announced on February 20, 2024, the execution of an underwriting agreement for the issuance and sale of $4.5 billion in aggregate principal amount of senior notes. This significant debt financing is structured across four tranches with varying maturity dates and interest rates, ranging from 5.450% due in 2031 to 6.100% due in 2064. The notes will be guaranteed on a senior unsecured basis by the parent company, HCA Healthcare, Inc., and are being issued under the company's existing Form S-3 registration statement. This debt offering is a material event for investors as it provides insight into HCA's capital structure management and financing strategy. The substantial capital raised may be intended for various corporate purposes, such as funding operations, acquisitions, refinancing existing debt, or general corporate expenditures. Investors should monitor how these funds are deployed and assess the impact on the company's leverage ratios and overall financial health. The specific terms of the notes, including their coupon rates and maturity profiles, reflect current market conditions and HCA's credit standing.
HCA Healthcare, Inc. 8-K Report, Financial Results (Jan 30, 2024)
HCA Healthcare, Inc. (HCA) filed an 8-K on January 30, 2024, reporting key financial and operational updates. The company announced its financial results for the fourth quarter and full year ended December 31, 2023, via a press release. Additionally, the filing disclosed significant leadership changes, including the retirement of Executive Vice President and Chief Financial Officer William B. Rutherford, effective May 1, 2024. Michael A. Marks, a long-time HCA employee with extensive finance experience within the company, has been appointed to succeed Mr. Rutherford, also effective May 1, 2024. In addition to personnel updates, HCA announced a substantial $6 billion share repurchase program authorization from its Board of Directors, signaling a commitment to returning capital to shareholders. The company also declared its quarterly cash dividend of $0.66 per share. These announcements collectively highlight HCA's financial performance, strategic capital allocation, and leadership transition.
HCA Healthcare, Inc. 8-K Report, Regulation FD Disclosure (Nov 9, 2023)
HCA Healthcare, Inc. (HCA) filed an 8-K on November 9, 2023, to disclose preliminary financial outlook and long-term targets in advance of their Investor Day. This early perspective aims to provide stakeholders with forward-looking insights into the company's strategic direction and growth potential. Investors should note that the information provided is intended to be a preview and further details will be discussed during the upcoming Investor Day presentations. The company also announced plans to webcast its Investor Day presentations and Q&A session, with materials to be made available on their Investor Relations website. This proactive communication strategy underscores HCA's commitment to transparency and engaging with its investor base on future financial objectives and operational strategies.
HCA Healthcare, Inc. 8-K Report, Financial Results (Oct 24, 2023)
HCA Healthcare, Inc. (HCA) filed an 8-K on October 24, 2023, primarily to announce its third-quarter 2023 financial results via an attached press release (Exhibit 99.1). While the 8-K itself does not contain detailed financial figures, it directs investors to the press release for operational and financial performance. This filing is crucial for investors seeking the latest financial updates and performance indicators from HCA, including revenue, earnings, and operational metrics for the most recent quarter. Additionally, the filing disclosed that HCA's Board of Directors declared a quarterly cash dividend of $0.60 per share, payable on December 28, 2023, to shareholders of record as of December 14, 2023. This dividend declaration signals the company's continued commitment to returning capital to its shareholders and provides a concrete income stream for investors.
HCA Healthcare, Inc. 8-K Report, Financial Results (Jul 27, 2023)
HCA Healthcare, Inc. (HCA) filed an 8-K on July 27, 2023, primarily to announce its financial results for the second quarter ended June 30, 2023, via a press release. While the specific financial metrics are detailed within the attached press release (Exhibit 99.1), this filing signals that the company is providing an update on its operational and financial performance for the most recent quarter. In addition to the quarterly results, HCA announced a quarterly cash dividend of $0.60 per share. This dividend, payable on September 29, 2023, to shareholders of record on September 15, 2023, demonstrates the company's commitment to returning capital to its shareholders. Investors should review the associated press release for comprehensive details on revenue, profitability, and any forward-looking guidance provided by HCA.
HCA Healthcare, Inc. 8-K Report, Corporate Update (Jul 10, 2023)
HCA Healthcare, Inc. (HCA) has filed an 8-K report on July 10, 2023, to disclose a significant data security incident. The company announced that a portion of its data, including patient information, was accessed and exfiltrated by an unauthorized third party. While HCA states it is still investigating the full scope of the incident, the preliminary assessment suggests that the accessed data included patient names, contact information, dates of birth, and potentially clinical information and social security numbers for a subset of patients. The company is working with external cybersecurity experts and has notified law enforcement.
HCA Healthcare, Inc. 8-K Report, Corporate Update (May 26, 2023)
HCA Healthcare, Inc. (HCA) has filed a Current Report on Form 8-K to disclose a reorganization of its operating segments. Effective January 1, 2023, the company transitioned from two geographically organized groups to three: the National, American, and Atlantic Groups. This report retrospectively revises the historical segment reporting financial information previously presented in the Company's Annual Report on Form 10-K for the year ended December 31, 2022. Investors should note that this filing does not restate or reclassify HCA's previously reported consolidated financial statements for any period. The purpose of this 8-K is solely to align historical segment data with the new operational structure. All other information within the 2022 Form 10-K remains unchanged. The revised segment information is provided in Exhibit 99.1.
HCA Healthcare, Inc. 8-K Report, Material Agreement (May 4, 2023)
HCA Healthcare, Inc. (HCA) announced the completion of a significant public offering of senior unsecured notes totaling $3.25 billion on May 4, 2023. This offering comprises three tranches: $1 billion in 5.200% Senior Notes due 2028, $1.25 billion in 5.500% Senior Notes due 2033, and $1 billion in 5.900% Senior Notes due 2053. These notes are issued by HCA Inc., a wholly owned subsidiary, and are guaranteed on a senior unsecured basis by the parent company, HCA Healthcare, Inc. The proceeds from this issuance are intended to fund general corporate purposes. This move diversifies HCA's debt maturity profile and provides substantial capital. From an investor's perspective, this filing indicates the company's proactive management of its capital structure and its ability to access public debt markets efficiently. The guaranteed nature of the notes by the parent company offers a strong layer of credit support. While the new debt increases HCA's overall leverage, the company has outlined standard covenants that aim to protect noteholders, including restrictions on liens, sale-leaseback transactions, and asset disposals. The inclusion of a change of control provision with a premium repurchase price for noteholders also provides a measure of protection against significant unfavorable corporate events.
HCA Healthcare, Inc. 8-K Report, Corporate Update (May 2, 2023)
HCA Healthcare, Inc. (HCA) has filed an 8-K report detailing a significant debt issuance. On May 1, 2023, the company, through its wholly-owned subsidiary HCA Inc., entered into an underwriting agreement to issue and sell $3.25 billion in senior notes. This offering is comprised of three tranches: $1 billion of 5.200% Senior Notes due 2028, $1.25 billion of 5.500% Senior Notes due 2033, and $1 billion of 5.900% Senior Notes due 2053. The Notes will be senior unsecured obligations, guaranteed by HCA Healthcare, Inc. The issuance is being conducted under the company's effective registration statement on Form S-3. This action signals a strategic move by HCA to raise substantial capital, likely to fund ongoing operations, potential acquisitions, or refinance existing debt under potentially more favorable terms. Investors should note the varying interest rates and maturity dates across the different tranches.
HCA Healthcare, Inc. 8-K Report, Financial Results (Apr 21, 2023)
HCA Healthcare, Inc. (HCA) filed an 8-K on April 21, 2023, primarily to announce its first-quarter 2023 financial results and a quarterly dividend. The company reported its operational and financial condition for the period ending March 31, 2023. This filing serves as a key update for investors regarding the company's performance and capital return strategy. In addition to the financial results, HCA's Board of Directors declared a quarterly cash dividend of $0.60 per share. This demonstrates a commitment to returning value to shareholders and provides a concrete return for the current quarter, payable on June 30, 2023. Investors should refer to the press release filed as Exhibit 99.1 for detailed financial information.
HCA Healthcare, Inc. 8-K Report, Executive Changes (Apr 21, 2023)
HCA Healthcare, Inc. (HCA) filed an 8-K on April 21, 2023, reporting the results of its Annual Meeting of Stockholders held on April 19, 2023. The primary focus of this filing is the outcome of various shareholder votes, including the election of directors, ratification of auditors, and approval of corporate plans. Notably, all ten director nominees were elected with substantial support, indicating shareholder confidence in the current leadership. The company's 2023 Employee Stock Purchase Plan also received strong approval from stockholders, signaling support for employee ownership and engagement initiatives. The filing also confirms the ratification of Ernst & Young LLP as the independent registered public accounting firm for the upcoming fiscal year, a standard but crucial vote for financial oversight. Additionally, shareholders approved an advisory resolution on executive compensation, reflecting general satisfaction with the company's compensation practices. Conversely, two shareholder proposals, one concerning political spending disclosure and another regarding an amendment to the Patient Safety and Quality of Care Committee charter, did not receive majority approval.
HCA Healthcare, Inc. 8-K Report, Executive Changes (Apr 6, 2023)
HCA Healthcare, Inc. (HCA) has filed an 8-K detailing its new 2023 Senior Officer Performance Excellence Program (Senior Officer PEP). This program outlines the incentive compensation structure for the company's executive officers, with awards weighted 80% towards EBITDA targets and 20% towards quality metrics. The program aims to align executive compensation with both financial performance and patient care quality. Key features include tiered payout structures for performance against targets, with specific award opportunities outlined for the CEO, CFO, COO, and Chief Legal Officer, expressed as percentages of their base salaries. The program also includes provisions for adjustments, clawbacks in certain circumstances, and is payable in cash. Investors should note the emphasis on EBITDA and specific quality indicators, which provides insight into HCA's strategic priorities for executive performance in 2023.
HCA Healthcare, Inc. 8-K/A Report, Executive Changes (Jan 30, 2023)
This 8-K Amendment from HCA Healthcare, Inc. (HCA) provides crucial updates on the compensation package for its newly appointed Executive Vice President and Chief Operating Officer, Jon M. Foster. While the initial appointment was announced in October 2022, this filing details material changes to Mr. Foster's compensation, approved by the Compensation Committee in January 2023. The key changes include an increase in base salary and a significant long-term equity incentive award, signaling the company's investment in key executive talent for its operational leadership. Investors should note the details of Mr. Foster's enhanced compensation, which includes a base salary adjustment to $1,000,000 and a substantial equity grant valued at $3,750,000. This equity award is structured with a mix of stock appreciation rights and performance share units, aligning a significant portion of his compensation with long-term company performance and shareholder value. This filing clarifies compensation details that were undetermined at the time of the initial appointment announcement.
HCA Healthcare, Inc. 8-K Report, Financial Results (Jan 27, 2023)
HCA Healthcare, Inc. (HCA) filed an 8-K on January 27, 2023, primarily to announce its financial results for the fourth quarter and full year ended December 31, 2022, as detailed in an accompanying press release (Exhibit 99.1). While the 8-K itself doesn't provide the granular financial figures, it signifies the official release of this operational and financial data, which investors should review in the linked press release for a comprehensive understanding of the company's performance during the reported periods. In addition to financial results, the filing disclosed significant capital allocation decisions by HCA's Board of Directors. The company announced an authorization of a new share repurchase program, allowing for up to $3 billion in stock buybacks, signaling management's confidence in the company's valuation and a commitment to returning capital to shareholders. Furthermore, HCA declared a quarterly cash dividend of $0.60 per share, reinforcing its policy of providing consistent income to its investors.
HCA Healthcare, Inc. 8-K Report, Material Agreement (Jan 4, 2023)
HCA Healthcare, Inc. (HCA) announced significant updates to its credit facilities through amendments and restatements filed on January 4, 2023. The primary focus of these changes involves the transition from LIBOR to Term SOFR as the benchmark interest rate for both its senior secured credit facility (Cash Flow Credit Facility) and its senior secured asset-based revolving credit facility (ABL Credit Facility). This transition is a critical step for HCA to align with evolving market standards and regulatory requirements, ensuring continued access to credit in a post-LIBOR environment. In addition to the benchmark rate transition, HCA has substantially increased its revolving credit capacity. The Cash Flow Credit Facility's revolving commitments have been expanded from $2.0 billion to $3.5 billion, maturing on June 30, 2026. This enhancement to its liquidity provides greater financial flexibility. Furthermore, HCA utilized proceeds from new ABL Credit Facility borrowings, combined with existing cash, to fully repay its $492.5 million in outstanding Tranche B term loans. These actions demonstrate proactive debt management and a strategic strengthening of the company's financial structure.
HCA Healthcare, Inc. 8-K Report, Bylaw Amendment (Dec 19, 2022)
This 8-K filing from HCA Healthcare, Inc. (HCA) announced an update to the company's bylaws, effective December 19, 2022. The Board of Directors, upon the recommendation of the Nominating and Corporate Governance Committee, adopted the Third Amended Bylaws. This amendment primarily focuses on updating provisions related to director nominations and proxy solicitations to align with current regulations, specifically requiring compliance with Rule 14a-19 of the Securities Exchange Act of 1934. While this filing does not contain significant financial information or operational changes, investors should note the proactive steps HCA is taking to ensure its corporate governance practices are up-to-date with regulatory requirements. The changes are described as technical, ministerial, clarifying, and conforming, suggesting a focus on maintaining compliance and good governance rather than a shift in strategic direction or financial performance.
HCA Healthcare, Inc. 8-K Report, Executive Changes (Oct 26, 2022)
HCA Healthcare, Inc. (HCA) filed an 8-K on October 25, 2022, primarily to announce a significant executive leadership change. Effective January 1, 2023, Jon M. Foster has been appointed as the new Executive Vice President and Chief Operating Officer (COO). Mr. Foster has a long tenure with HCA, holding various leadership positions within different groups and divisions since joining the company in 2001, most recently as President of the American Group since 2013. This appointment signals continuity and internal promotion within the company's operational leadership. Investors should note that the specific compensation details for Mr. Foster in his new role have not yet been determined and will be disclosed in future filings. The press release accompanying this filing also indicates other organizational changes, suggesting ongoing strategic adjustments within HCA Healthcare.
HCA Healthcare, Inc. 8-K Report, Financial Results (Oct 21, 2022)
HCA Healthcare, Inc. (HCA) filed an 8-K on October 21, 2022, primarily to report its third-quarter 2022 financial results and announce a quarterly cash dividend. The press release, incorporated by reference, provides details on the company's performance during the quarter ended September 30, 2022. Investors should review this press release for comprehensive financial and operational metrics. In addition to the financial results, HCA's Board of Directors declared a quarterly cash dividend of $0.56 per share. This dividend, payable on December 28, 2022, to shareholders of record as of December 14, 2022, reflects the company's commitment to returning capital to its shareholders. The filing serves as a crucial update on HCA's financial health and capital allocation strategies.
HCA Healthcare, Inc. 8-K Report, Executive Changes (Aug 17, 2022)
This 8-K filing announces the upcoming retirement of Charles J. Hall, President of HCA Healthcare's National Group, effective December 31, 2022. While Mr. Hall's departure is not immediate, it marks a significant leadership change within a key operational segment of the company. Investors should monitor the announcement of his successor, as this individual will play a crucial role in the strategic direction and operational performance of the National Group, which is likely a substantial contributor to HCA's overall revenue and profitability.
HCA Healthcare, Inc. 8-K Report, Financial Results (Jul 22, 2022)
HCA Healthcare, Inc. announced its second quarter 2022 results on July 22, 2022, through a press release that also detailed its financial condition. While the 8-K filing itself doesn't provide the specific financial figures, it points to an accompanying press release (Exhibit 99.1) for these details. Investors should review this press release for key performance indicators, revenue figures, profitability metrics, and operational performance for the quarter ended June 30, 2022. The company's operational performance and financial health in Q2 2022 are crucial for understanding its current trajectory and future outlook.
HCA Healthcare, Inc. 8-K Report, Corporate Update (May 26, 2022)
HCA Healthcare, Inc. (HCA) announced that Standard & Poor's Rating Services (S&P) has issued an investment grade rating for the company and its subsidiaries. This event, combined with prior disclosures, triggers an 'Investment Grade Rating Event' under the terms of its Senior Secured Indentures. As a result, HCA can now permanently release subsidiary guarantees and collateral securing its Senior Secured Notes. The company has taken the necessary steps to effect this release. Additionally, covenants governing pre-2019 Senior Secured Notes will align with those of more recent senior secured and senior unsecured notes, simplifying the company's debt structure. The change of control put at 101% for both senior secured and senior unsecured notes will also be suspended. These changes are positive indicators of financial strength and operational flexibility for HCA.